High-throughput imaging of cardiac microtissues for the assessment of cardiac contraction during drug discovery

Toxicological Sciences

Volumn 155, Issue 2, 2017, Pages 444-457

  Pointon, Amy ^a   Pilling, James ^a   Dorval, Thierry ^a   Wang, Yinhai ^a   Archer, Caroline ^a   Pollard, Christopher ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cardiotoxicity; Drug discovery and development; HiPS CMs

Indexed keywords

DOBUTAMINE; MILRINONE; QUINIDINE; VERAPAMIL;

ADULT; ARTICLE; CARDIAC ENDOTHELIAL CELL; CARDIAC MICROTISSUE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; EC50; ENDOTHELIUM CELL; HEART FIBROBLAST; HEART MUSCLE CONTRACTILITY; HEART TISSUE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; INOTROPISM; MALE; OPTIC FLOW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; WORKFLOW; YOUNG ADULT; CELL CULTURE; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION; HEART CONTRACTION; PROCEDURES; ULTRASTRUCTURE;

CELLS, CULTURED; DRUG DISCOVERY; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC;

EID: 85021725293     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw227     Document Type: Article

References (52)

1. Abi-Gerges, N., Pointon, A., Pullen, G. F., Morton, M. J., Oldman, K. L., Armstrong, D., Valentin, J. P., and Pollard, C. E. (2013). Preservation of cardiomyocytes from the adult heart. J. Mol. Cell. Cardiol. 64, 108-119
2. Ahmad, S. R., Singer, S. J., and Leissa, B. G. (2001). Congestive heart failure associated with itraconazole. Lancet 357, 1766-1767
3. Brown, L., and Erdmann, E. (1985). Concentration-response curves of positive inotropic agents before and after ouabain pretreatment. Cardiovasc. Res. 19, 288-298
4. Brox, T., Bruhn, A., Papenberg, N., and Weickert, J. (2004). High accuracy optical flow estimation based on a theory for warping. European Conference on Computer Vision (ECCV), Springer, LNCS Vol. 3024, pp. 25-36
5. Brutsaert, D. L. (2003). Cardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity. Physiol. Rev. 83, 59-115
6. Butler, L., Cros, C., Oldman, K. L., Harmer, A. R., Pointon, A., Pollard, C. E., and Abi-Gerges, N. (2015). Enhanced characterization of contractility in cardiomyocytes during early drug safety assessment. Toxicol. Sci. 145, 396-406
7. Camelliti, P., Borg, T. K., and Kohl, P. (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65, 40-51
8. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M. N. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: A fivedimensional framework. Nat. Rev. Drug Discov. 13, 419-431
9. Force, T., Krause, D. S., and Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332-344
10. Funck-Brentano, C. (1993). Rate-dependence of class III actions in the heart. Fundam. Clin. Pharmacol. 7, 51-59
11. Genschow, E., Spielmann, H., Scholz, G., Seiler, A., Brown, N., Piersma, A., Brady, M., Clemann,N., Huuskonen, H., Paillard, F., et al. (2002). The ECVAM international validation study on in vitro embryotoxicity tests: Results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 30, 151-176
12. Grosberg, A., Alford, P. W., McCain, M. L., and Parker, K. K. (2011). Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chip. Lab. Chip. 11, 4165-4173
13. Grosberg, A., Nesmith, A. P., Goss, J. A., Brigham, M. D., McCain, M. L., and Parker, K. K. (2012). Muscle on a chip: In vitro contractility assays for smooth and striated muscle. J. Pharmacol. Toxicol. Methods 65, 126-135
14. Guo, L., Dong, Z., and Guthrie, H. (2009). Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Methods 60, 130-151
15. Harmer, A. R., Abi-Gerges, N., Morton, M. J., Pullen, G. F., Valentin, J. P., and Pollard, C. E. (2012). Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicol. Appl. Pharmacol. 260, 162-172
16. Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H., Kanda, Y., Kurokawa, J., and Furukawa, T. (2014). Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. J. Mol. Cell. Cardiol. 77, 178-191
17. Hwang, H. S., Kryshtal, D. O., Feaster, T. K., Sanchez-Freire, V., Zhang, J., Kamp, T. J., Hong, C. C., Wu, J. C., and Knollmann, B. C. (2015). Comparable calcium handling of human iPSCderived cardiomyocytes generated by multiple laboratories. J. Mol. Cell. Cardiol. 85, 79-88
18. Kennedy, D., Omran, E., Periyasamy, S. M., Nadoor, J., Priyadarshi, A., Willey, J. C., Malhotra, D., Xie, Z., and Shapiro, J. I. (2003). Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J. Am. Soc. Nephrol. 14, 90-97
19. Kijlstra, J. D., Hu, D., Mittal, N., Kausel, E., van der Meer, P., Garakani, A., and Domian, I. J. (2015). Integrated analysis of contractile kinetics, force generation, and electrical activity in single human stem cell-derived cardiomyocytes. stem cell. Reports 5, 1226-1238
20. Lasko, T. A., Bhagwat, J. G., Zou, K. H., and Ohno-Machado, L. (2005). The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inform. 38, 404-415
21. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 163, 675-693
22. Lin, Z., and Will, Y. (2012). Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol. Sci. 126, 114-127
23. Lo, C. M., Wang, H. B., Dembo, M., and Wang, Y. L. (2000). Cell movement is guided by the rigidity of the substrate. Biophys. J. 79, 144-152
24. Lu, H. R., Whittaker, R., Price, J. H., Vega, R., Pfeiffer, E. R., Cerignoli, F., Towart, R., and Gallacher, D. J. (2015). High throughput measurement of Ca++ dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometery: A cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds. Toxicol. Sci. 148, 503-516
25. Ma, J., Guo, L., Anson, B. D., Fiene, S. J., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., and January, C. T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017
26. Matsuoka, S., Nawada, T., Hisatome, I., Miyamoto, J., Hasegawa, J., Kotake, H., and Mashiba, H. (1991). Comparison of Ca2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. Gen. Pharmacol. 22, 87-91
27. Mellor, H. R., Bell, A. R., Valentin, J. P., and Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14-32
28. Morton, M. J., Armstrong, D., Abi Gerges, N., Bridgland-Taylor, M., Pollard, C. E., Bowes, J., and Valentin, J. P. (2014). Predicting changes in cardiac myocyte contractility during early drug discovery with in vitro assays. Toxicol. Appl. Pharmacol. 279, 87-94
29. Murphy, C. A., and Dargie, H. J. (2007). Drug-induced cardiovascular disorders. Drug Saf. 30, 783-804
30. Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013). Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128, S3-13
31. O'Connor, C. M., Gattis, W. A., Uretsky, B. F., Adams, K. F., Jr., McNulty, S. E., Grossman, S. H., McKenna, W. J., Zannad, F., Swedberg, K., Gheorghiade, M., et al. (1999). Continuous intravenous dobutamine is associated with an inceased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trail (FRIST). Am. Heart J. 138, 78-86
32. Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., and Kukin, M. L. (1991). Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325, 1468-1475
33. Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L., and Neuvonen, P. (1993). Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45, 191-193
34. Pointon, A., Harmer, A. R., Dale, I. L., Abi-Gerges, N., Bowes, J., Pollard, C., and Garside, H. (2015). Assessment of cardiomyocyte contraction in human-induced pluripotent stem cellderived cardiomyocytes. Toxicol. Sci. 144, 227-237
35. Pollard, C. E., Abi Gerges, N., Bridgland-Taylor, M. H., Easter, A., Hammond, T. G., and Valentin, J. P. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159, 12-21
36. Pollard, C. E., Valentin, J. P., and Hammond, T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: A pharmaceutical company perspective. Br. J. Pharmacol. 154, 1538-1543
37. Ravenscroft, S. M., Pointon, A., Williams, A. W., Cross, M. J., and Sidaway, J. E. (2016). Cardiac non-myocyte cells show enhanced pharmacological function suggestive of contractile maturity in stem cell derived cardiomyocyte microtissues. Toxicol. Sci. 152, 99-112
38. Ribeiro, A. J., Ang, Y. S., Fu, J. D., Rivas, R. N., Mohamed, T. M., Higgs, G. C., Srivastava, D., and Pruitt, B. L. (2015). Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc. Natl. Acad. Sci. U. S. A. 112, 12705-12710
39. Schwinger, R. H., Bohm, M., and Erdmann, E. (1990). Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. J. Cardiovasc. Pharmacol. 15, 892-899
40. Scott, C. W., Zhang, X., Abi-Gerges, N., Lamore, S. D., Abassi, Y. A., and Peters, M. F. (2014). An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol. Sci. 142, 331-338
41. Sirenko, O., Cromwell, E. F., Crittenden, C., Wignall, J. A., Wright, F. A., and Rusyn, I. (2013). Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol. Appl. Pharmacol. 273, 500-507
42. Skinner, M., Lainee, P., Valentin, J.-P., and Moors, J. (2012). Assessment of left ventricular dP/dtmax in telemetry studies: Essential or excessive. J Pharmacol. Toxicol. Methods, 66, 175
43. Slordal, L., and Spigset, O. (2006). Heart failure induced by noncardiac drugs. Drug Saf. 29, 567-586
44. Souders, C. A., Bowers, S. L., and Baudino, T. A. (2009). Cardiac fibroblast: The renaissance cell. Circ. Res. 105, 1164-1176
45. Spielmann, H., Seiler, A., Bremer, S., Hareng, L., Hartung, T., Ahr, H., Faustman, E., Haas, U., Moffat, G. J., Nau, H., et al. (2006). The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern. Lab. Anim. 34, 527-538
46. Tamargo, J., Caballero, R., Gomez, R., Barana, A., Amoros, I., and Delpon, E. (2009). Investigational positive inotropic agents for acute heart failure. Cardiovasc. Hematol. Disord. Drug Targets 3, 193-205
47. Tuttle, R. R., and Mills, J. (1975). Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility. Circ. Res. 36, 185-196
48. Wallis, R., Gharanei, M., and Maddock, H. (2015). Predictivity of in vitro non-clinical cardiac contractility assays for inotropic effects in humans-A literature search. J. Pharmacol. Toxicol. Methods 75, 62-69
49. Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475-486
50. Weir, A. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475-486
51. Xi, B., Wang, T., Li, N., Ouyang, W., Zhang, W., Wu, J., Xu, X., Wang, X., and Abassi, Y. A. (2011). Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J. Lab. Autom. 16, 415-421
52. Yamakawa, K., Rajendran, P. S., Takamiya, T., Yagishita, D., So, E. L., Mahajan, A., Shivkumar, K., and Vaseghi, M. (2015). Vagal nerve stimulation activates vagal afferent fibers that reduce cardiac efferent parasympathetic effects. Am. J. Physiol. Heart Circ. Physiol. 309, H1579-H1590